retatrutide trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Triumph-1 Trial Results for Retatrutide

It means the fat loss it produces removes a hormonal roadblock that many men do not even realize exists

A new study using fitness tracker data reveals that older adults taking GLP-1 weight loss medications are exercising less, which could lead to unintended consequences, like overall weakness

Mild side effects such as nausea, vomiting, diarrhea, and constipation were more frequent in the retatrutide group

Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart

In GBC, several molecular factors have been implicated in ferroptosis regulation

By backing this innovative research, and inspiring the next generation of specialists, we can enhance quality of life for millions affected by arthritis